CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

NCT01664910 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Interventions

PROCEDURE: Allogeneic Bone Marrow Transplantation
PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
BIOLOGICAL: Anti-Thymocyte Globulin
DRUG: Bendamustine Hydrochloride
DRUG: Fludarabine Phosphate
BIOLOGICAL: Inotuzumab Ozogamicin
DRUG: Methotrexate
PROCEDURE: Peripheral Blood Stem Cell Transplantation
BIOLOGICAL: Rituximab
DRUG: Tacrolimus

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]